The relationship between bone mineral density and levels of RANKL , osteoprotegerin and cathepsin-K in patients with rheumatoid arthritis

Dicle Tıp Derg / Dicle Med J www.diclemedj.org Cilt / Vol 39, No 4, 479-484 1 Ceylanpınar State Hospital, Department of Biochemistry, Şanlıurfa, Turkey 2 Dicle University Faculty of Medicine, Department of Biochemistry, Diyarbakır, Turkey 3 Dicle University Faculty of Medicine, Dept Physical Medicine and Rehabilitation, Diyarbakır, Turkey 4 Batman State Hospital, Dept., Physical Medicine and Rehabilitation, Batman, Turkey 5 Dicle University Faculty of Medicine, Dept., Family Medicine, Diyarbakır, Turkey Yazışma Adresi /Correspondence: Dr. Mustafa Akif Sariyildiz, Dicle University Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Diyarbakır, Turkey Email: makifsariyildiz@hotmail.com Geliş Tarihi / Received: 21.09.2012, Kabul Tarihi / Accepted: 23.10.2012 Copyright © Dicle Tıp Dergisi 2012, Her hakkı saklıdır / All rights reserved Dicle Tıp Dergisi / 2012; 39 (4): 47984 Dicle Medical Journal doi: 10.5798/diclemedj.0921.2012.04.0186

[1]  Jian-hua Xu,et al.  Osteoprotegerin and RANKL in the pathogenesis of rheumatoid arthritis-induced osteoporosis , 2012, Rheumatology International.

[2]  R. Recker,et al.  Pathophysiology of osteoporosis: new mechanistic insights. , 2012, Endocrinology and metabolism clinics of North America.

[3]  K. Malizos,et al.  OSTEOPROTEGERIN, RANK AND RANKL EXPRESSION IN THE FEMORAL HEAD OF PATIENTS WITH AVN , 2010 .

[4]  D. M. van der Heijde,et al.  Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. , 2008, Arthritis and rheumatism.

[5]  Brendan F Boyce,et al.  Biology of RANK, RANKL, and osteoprotegerin , 2007, Arthritis research & therapy.

[6]  M. McClung.  Role of RANKL inhibition in osteoporosis , 2007, Arthritis research & therapy.

[7]  S. Franke,et al.  Soluble receptor activator of NFkappa B-ligand and osteoprotegerin in rheumatoid arthritis - relationship with bone mineral density, disease activity and bone turnover , 2007, Clinical Rheumatology.

[8]  D. Heymann,et al.  RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases , 2007, Cellular and Molecular Life Sciences.

[9]  Teruo Tanaka,et al.  Cathepsins in the osteoclast. , 2003, Journal of electron microscopy.

[10]  T. Martin,et al.  Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. , 2002, The American journal of pathology.

[11]  R. Gordon,et al.  Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. , 2001, The American journal of pathology.

[12]  G. Bain,et al.  Osteoprotegerin and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclast formation by cells in the human rheumatoid arthritic joint. , 2001, Rheumatology.

[13]  P. Kostenuik,et al.  Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. , 2001, Current pharmaceutical design.

[14]  I. James,et al.  Biosynthesis and processing of cathepsin K in cultured human osteoclasts. , 2001, Bone.

[15]  G. Haugeberg,et al.  Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. , 2000, Arthritis and rheumatism.

[16]  S. Goldring,et al.  Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor. , 2000, Arthritis and rheumatism.

[17]  Brian R. Wong,et al.  TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells* , 1997, The Journal of Biological Chemistry.

[18]  N. Maalouf,et al.  The Role of Receptor Activator of Nuclear Factor-B ( RANK ) / RANK Ligand / Osteoprotegerin : Clinical Implications , 2007 .

[19]  J. Głodzik,et al.  [Incidence of osteoporosis in patients with rheumatoid arthritis]. , 2000, Przeglad lekarski.

[20]  P. Delmas.  The role of markers of bone turnover in the assessment of fracture risk in postmenopausal women. , 1998, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.